An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects

Mark Borchert,1 Suzanne Bruce,2 David Wirta,3 Steven G Yoelin,4 Sungwook Lee,5 Cheri Mao,5 Amanda VanDenburgh5 1Children’s Hospital Los Angeles, Los Angeles, CA, USA; 2Suzanne Bruce and Associates, PA, Houston, TX, USA; 3David Wirta and Associates, Newport Beach, CA, USA; 4Medical Associa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Borchert M, Bruce S, Wirta D, Yoelin SG, Lee S, Mao C, VanDenburgh A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	adolescent child hypotrichosis Latisse Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2607e9caf70b4212979686d572a02a48
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2607e9caf70b4212979686d572a02a48
record_format	dspace
spelling	oai:doaj.org-article:2607e9caf70b4212979686d572a02a482021-12-02T06:34:19ZAn evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects1177-5483https://doaj.org/article/2607e9caf70b4212979686d572a02a482016-03-01T00:00:00Zhttps://www.dovepress.com/an-evaluation-of-the-safety-and-efficacy-of-bimatoprost-for-eyelash-gr-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Mark Borchert,1 Suzanne Bruce,2 David Wirta,3 Steven G Yoelin,4 Sungwook Lee,5 Cheri Mao,5 Amanda VanDenburgh5 1Children’s Hospital Los Angeles, Los Angeles, CA, USA; 2Suzanne Bruce and Associates, PA, Houston, TX, USA; 3David Wirta and Associates, Newport Beach, CA, USA; 4Medical Associates Inc., Newport Beach, CA, USA; 5Allergan plc, Irvine, CA, USA Purpose: Evaluate the safety and effectiveness of bimatoprost 0.03% for treatment of eyelash hypotrichosis in a pediatric population. Patients and methods: This multicenter, randomized, double-masked, parallel-group study was conducted at seven sites in the US and Brazil. Subjects with eyelash hypotrichosis caused by chemotherapy or alopecia areata (aged 5–17 years) or healthy adolescents aged 15–17 years were enrolled (N=71). Subjects applied bimatoprost 0.03% or vehicle to upper eyelid margins once nightly for 4 months and were followed for 1 month post-treatment. Eyelash prominence was assessed using the validated 4-grade Global Eyelash Assessment scale with photonumeric guide. Changes in eyelash length, thickness, and darkness were measured by digital image analysis. Safety was assessed by adverse events and ophthalmic observations. Results: Eyelash prominence improved in a significantly greater proportion of subjects treated with bimatoprost compared with vehicle at month 4 (70.8% versus 26.1%; P<0.001). This benefit was sustained at month 5 post-treatment assessment. Digital image analysis measures were significantly improved with bimatoprost. Significant treatment benefits with bimatoprost versus vehicle were evident among the healthy adolescents but not in the postchemotherapy or alopecia areata subgroups. The safety profile of bimatoprost was consistent with previous studies in adults. Conclusion: Bimatoprost was safe and well tolerated in pediatric subjects with eyelash hypotrichosis. In this study with limited sample size, subgroup analyses showed that treatment was effective in healthy adolescents with no concurrent contributing medical condition, but not in those with eyelash hypotrichosis due to chemotherapy or alopecia areata. Keywords: adolescent, child, hypotrichosis, Latisse Borchert MBruce SWirta DYoelin SGLee SMao CVanDenburgh ADove Medical PressarticleadolescentchildhypotrichosisLatisseOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 419-429 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	adolescent child hypotrichosis Latisse Ophthalmology RE1-994
spellingShingle	adolescent child hypotrichosis Latisse Ophthalmology RE1-994 Borchert M Bruce S Wirta D Yoelin SG Lee S Mao C VanDenburgh A An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
description	Mark Borchert,1 Suzanne Bruce,2 David Wirta,3 Steven G Yoelin,4 Sungwook Lee,5 Cheri Mao,5 Amanda VanDenburgh5 1Children’s Hospital Los Angeles, Los Angeles, CA, USA; 2Suzanne Bruce and Associates, PA, Houston, TX, USA; 3David Wirta and Associates, Newport Beach, CA, USA; 4Medical Associates Inc., Newport Beach, CA, USA; 5Allergan plc, Irvine, CA, USA Purpose: Evaluate the safety and effectiveness of bimatoprost 0.03% for treatment of eyelash hypotrichosis in a pediatric population. Patients and methods: This multicenter, randomized, double-masked, parallel-group study was conducted at seven sites in the US and Brazil. Subjects with eyelash hypotrichosis caused by chemotherapy or alopecia areata (aged 5–17 years) or healthy adolescents aged 15–17 years were enrolled (N=71). Subjects applied bimatoprost 0.03% or vehicle to upper eyelid margins once nightly for 4 months and were followed for 1 month post-treatment. Eyelash prominence was assessed using the validated 4-grade Global Eyelash Assessment scale with photonumeric guide. Changes in eyelash length, thickness, and darkness were measured by digital image analysis. Safety was assessed by adverse events and ophthalmic observations. Results: Eyelash prominence improved in a significantly greater proportion of subjects treated with bimatoprost compared with vehicle at month 4 (70.8% versus 26.1%; P<0.001). This benefit was sustained at month 5 post-treatment assessment. Digital image analysis measures were significantly improved with bimatoprost. Significant treatment benefits with bimatoprost versus vehicle were evident among the healthy adolescents but not in the postchemotherapy or alopecia areata subgroups. The safety profile of bimatoprost was consistent with previous studies in adults. Conclusion: Bimatoprost was safe and well tolerated in pediatric subjects with eyelash hypotrichosis. In this study with limited sample size, subgroup analyses showed that treatment was effective in healthy adolescents with no concurrent contributing medical condition, but not in those with eyelash hypotrichosis due to chemotherapy or alopecia areata. Keywords: adolescent, child, hypotrichosis, Latisse
format	article
author	Borchert M Bruce S Wirta D Yoelin SG Lee S Mao C VanDenburgh A
author_facet	Borchert M Bruce S Wirta D Yoelin SG Lee S Mao C VanDenburgh A
author_sort	Borchert M
title	An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
title_short	An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
title_full	An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
title_fullStr	An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
title_full_unstemmed	An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
title_sort	evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/2607e9caf70b4212979686d572a02a48
work_keys_str_mv	AT borchertm anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT bruces anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT wirtad anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT yoelinsg anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT lees anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT maoc anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT vandenburgha anevaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT borchertm evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT bruces evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT wirtad evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT yoelinsg evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT lees evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT maoc evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects AT vandenburgha evaluationofthesafetyandefficacyofbimatoprostforeyelashgrowthinpediatricsubjects
_version_	1718399800057004032

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects

Ejemplares similares